Stocktoria
BIOCRYST PHARMACEUTICALS INC BCRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1994-03-04
BIOCRYST PHARMACEUTICALS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M |
| R&D expense | $166.1M | $174.6M | $216.6M | $253.3M | $208.8M |
| SG&A expense | $348.6M | $266.3M | $214.1M | $159.4M | $118.8M |
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M | -$177.7M |
| Interest expense | — | — | $108.2M | $99.1M | $59.3M |
| Income tax | $3.5M | $1.9M | $310,000 | $2.7M | $2.3M |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M | -$184.1M |
| EPS (diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Operating cash flow | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M |
| Cash & equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M |
| Inventory | $5.4M | $8.1M | $28.7M | $27.5M | $15.8M |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M |
| Total liabilities | $633.3M | $966.4M | $972.5M | — | — |
| Shareholders' equity | -$119.2M | -$475.9M | -$455.5M | -$294.6M | -$107.0M |
Source: SEC EDGAR filings · CIK 0000882796 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.